2024Antimicrobial agents and chemotherapy68 (3) : e0121023
Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets
Haid S, Matthaei A, Winkler M, Sake S, Gunesch A, Milke V, Köhler N, Rückert J, Vieyres G, Kühl D, Nguyen T, Göhl M, Lasswitz L, Zapatero-Belinchón F, Brogden G, Gerold G, Wiegmann B, Bilitewski U, Brown R, Brönstrup M, Schulz T, Pietschmann T
2024Nature communications15 (1) : 1173
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor
Sake S, Zhang X, Rajak M, Urbanek-Quaing M, Carpentier A, Gunesch A, Grethe C, Matthaei A, Rückert J, Galloux M, Larcher T, Le Goffic R, Hontonnou F, Chatterjee A, Johnson K, Morwood K, Rox K, Elgaher W, Huang J, Wetzke M, Hansen G, Fischer N, Eléouët J, Rameix-Welti M, Hirsch A, Herold E, Empting M, Lauber C, Schulz T, Krey T, Haid S, Pietschmann T
2024Frontiers in immunology15 : 1443665
A clinical protocol for a German birth cohort study of the Maturation of Immunity Against respiratory viral Infections (MIAI)
Hartmann C, Khan R, Schöning J, Richter M, Willers M, Pirr S, Heckmann J, Dirks J, Morbach H, Konrad M, Fries E, Winkler M, Büchel J, Seidenspinner S, Fischer J, Vollmuth C, Meinhardt M, Marissen J, Schmolke M, Haid S, Pietschmann T, Backes S, Dölken L, Löber U, Keil T, Heuschmann P, Wöckel A, Sagar, Ulas T, Forslund-Startceva S, Härtel C, Viemann D